Abstract
Botulinum toxin type A (Botox®) is increasingly used in the management of migraine and tension-type headaches. The results from small placebo-controlled trials and extensive open-label experience has suggested a significant role for this neurotoxin in the management of refractory headache. Several large placebo-controlled trials of episodic and chronic migraine are currently underway.